Related Experiment Video
Updated: Feb 26, 2026

Author Spotlight: Collecting the Brain and Serum from the Same Mice Fetus to Study Brain Tumor Development
Published on: May 17, 2024
Association of Antidepressant Medication Use During Pregnancy With Intellectual Disability in Offspring
Alexander Viktorin1,2,3, Rudolf Uher4, Alexander Kolevzon1,2
1Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York.
Insights
Maternal antidepressant use during pregnancy was not linked to intellectual disability (ID) in offspring after accounting for confounding factors. Parental mental illness may explain any observed associations, not the medication itself.
Area of Science:
- Perinatal Psychiatry
- Developmental Neuroscience
- Pharmacoepidemiology
Background:
- Maternal antidepressant use in pregnancy is common, yet its association with offspring intellectual disability (ID) remains under-investigated.
- Previous studies suggest links between prenatal medication exposure and adverse developmental outcomes.
- Understanding this association is crucial for clinical guidance and parental counseling.
Purpose of the Study:
- To investigate the association between maternal antidepressant medication use during pregnancy and the risk of intellectual disability (ID) in offspring.
- To explore the role of parental mental illness as a potential confounder in this association.
Main Methods:
- A population-based cohort study included 179,007 children born between 2006 and 2007, with follow-up through 2014.
- Relative risks (RRs) of ID were estimated for children exposed to antidepressants versus unexposed, with adjustments for confounders.
- A subsample analysis compared exposed mothers with unexposed mothers who had a history of depression or anxiety.
Main Results:
- The unadjusted analysis showed an increased risk of ID in offspring exposed to maternal antidepressants.
- After adjusting for confounding factors, no significant association was found between maternal antidepressant use during pregnancy and offspring ID (RR, 1.33; 95% CI, 0.90-1.98).
- Subgroup analyses for selective serotonin reuptake inhibitors (SSRIs) and other psychotropic medications yielded similar non-significant results.
Conclusions:
- The study found no evidence of an association between maternal antidepressant use during pregnancy and intellectual disability in offspring after adjusting for confounders.
- The observed association may be attributed to underlying factors such as parental age and maternal psychiatric disorders.
- These findings suggest that the benefits of treating maternal depression during pregnancy may outweigh the potential risks related to offspring ID.
Importance:
Maternal antidepressant medication use during pregnancy has previously been associated with adverse outcomes in offspring, but to our knowledge, the association with intellectual disability (ID) has not been investigated.
Objectives:
To examine the association of maternal antidepressant medication use during pregnancy with ID in offspring and investigate the importance of parental mental illness for such an association.
Design, Setting, And Participants:
A population-based cohort study of 179 007 children born from January 1, 2006, through December 31, 2007, with complete parental information from national registers who were followed up from birth throughout 2014.
Main Outcomes And Measures:
We estimated relative risks (RRs) and 95% CIs of ID in children exposed during pregnancy to any antidepressant medication or specifically to selective serotonin reuptake inhibitor (SSRI) antidepressants, all other non-SSRI antidepressants, or other nonantidepressant psychotropic medications. Analyses were adjusted for potential confounders. In addition to full population analyses, we used a subsample to compare mothers who used antidepressants during pregnancy with mothers who had at least one diagnosis of depression or anxiety before childbirth but did not use antidepressants during pregnancy.
Results:
Of the 179 007 children included in the study (mean [SD] age at end of follow-up, 7.9 [0.6] years; 92 133 [51.5%] male and 86 874 [48.5%] female), ID was diagnosed in 37 children (0.9%) exposed to antidepressants and in 819 children (0.5%) unexposed to antidepressants. With adjustment for potential confounders, the RR of ID after antidepressant exposure was estimated at 1.33 (95% CI, 0.90-1.98) in the full population sample and 1.64 (95% CI, 0.95-2.83) in the subsample of women with depression. Results from analyses of SSRI antidepressants, non-SSRI antidepressants, and nonantidepressant psychotropic medications and analyses in the clinically relevant subsample did not deviate from the full-sample results.
Conclusions And Relevance:
The unadjusted RR of ID was increased in offspring born to mothers treated with antidepressants during pregnancy. After adjustment for confounding factors, however, the current study did not find evidence of an association between ID and maternal antidepressant medication use during pregnancy. Instead, the association may be attributable to a mechanism integral to other factors, such as parental age and mother's psychiatric disorder.
More Related Videos
19:15Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
09:09Generating a Reproducible Model of Mid-Gestational Maternal Immune Activation using PolyI:C to Study Susceptibility and Resilience in Offspring
Published on: August 17, 2022
Related Concept Videos
Intellectual Disability
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview
Teratogenicity
Environmental Influences on Intelligence
Autism Spectrum Disorder
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.